MX2020005447A - Compuestos de furanopirimidina sustituida como inhibidores de pde1. - Google Patents
Compuestos de furanopirimidina sustituida como inhibidores de pde1.Info
- Publication number
- MX2020005447A MX2020005447A MX2020005447A MX2020005447A MX2020005447A MX 2020005447 A MX2020005447 A MX 2020005447A MX 2020005447 A MX2020005447 A MX 2020005447A MX 2020005447 A MX2020005447 A MX 2020005447A MX 2020005447 A MX2020005447 A MX 2020005447A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- treating
- sup
- cognitive
- methods
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- -1 furanopyrimidine chemical entities Chemical class 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000021267 infertility disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762591105P | 2017-11-27 | 2017-11-27 | |
| PCT/US2018/062493 WO2019104285A1 (en) | 2017-11-27 | 2018-11-26 | Substituted furanopyrimidine compounds as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005447A true MX2020005447A (es) | 2020-12-03 |
Family
ID=64665119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005447A MX2020005447A (es) | 2017-11-27 | 2018-11-26 | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
| MX2023004603A MX2023004603A (es) | 2017-11-27 | 2020-07-13 | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004603A MX2023004603A (es) | 2017-11-27 | 2020-07-13 | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11434247B1 (https=) |
| EP (1) | EP3717488B1 (https=) |
| JP (1) | JP7254078B2 (https=) |
| KR (1) | KR102794907B1 (https=) |
| CN (1) | CN111655695B (https=) |
| AU (1) | AU2018373258B2 (https=) |
| CA (1) | CA3120971A1 (https=) |
| DK (1) | DK3717488T3 (https=) |
| ES (1) | ES2902365T3 (https=) |
| MX (2) | MX2020005447A (https=) |
| WO (1) | WO2019104285A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| JP2022541954A (ja) * | 2019-07-17 | 2022-09-28 | 小野薬品工業株式会社 | Ｋｄｍ５阻害活性を有する化合物およびその医薬用途 |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| CA3198635A1 (en) * | 2020-12-03 | 2022-06-09 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| JP2024529020A (ja) * | 2021-08-06 | 2024-08-01 | レイゼビオ，インク． | 細胞内ｋｒａｓ ｇ１２ｃタンパク質を標的とするための共有結合剤を含むコンジュゲート |
| US20250049748A1 (en) * | 2021-12-16 | 2025-02-13 | Terran Biosciences Inc. | Analogs of 4-bromo-2,5-dimethoxyphenethylamine |
| CN117263843A (zh) * | 2023-06-16 | 2023-12-22 | 常州大学 | 一种多巴胺d2样受体双位配体化合物及其应用 |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
| WO2025255013A1 (en) * | 2024-06-03 | 2025-12-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN121159506A (zh) * | 2024-06-17 | 2025-12-19 | 青岛清原化合物有限公司 | 取代的芳基酰胺化合物或其盐及其制备方法、组合物和应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077372A1 (de) | 1981-04-22 | 1983-04-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| ZA914727B (en) | 1990-06-21 | 1992-03-25 | Schering Corp | Polycyclic guanine derivatives |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| WO1994019351A1 (en) | 1993-02-26 | 1994-09-01 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| JP3713783B2 (ja) | 1995-01-20 | 2005-11-09 | 大正製薬株式会社 | １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体 |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| CZ280697A3 (cs) | 1995-03-10 | 1998-04-15 | Sanofi Pharmaceuticals, Inc. | 6 aryl-pyrazolo(3,4-d)pyrimidin-4-ony a kompozice je obsahující, a způsob jejich použití |
| US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
| ZA969888B (en) | 1995-11-28 | 1997-05-26 | Schering Corp | 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones |
| US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| DE19838300A1 (de) | 1998-08-24 | 2000-03-02 | Bayer Ag | 9-Dialkylaminopurinon-derivate |
| GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| KR100297814B1 (ko) | 1998-12-29 | 2001-10-26 | 조민호 | 피라졸로피리미디논유도체와이의제조방법그리고이의용도 |
| WO2002009713A2 (de) | 2000-08-01 | 2002-02-07 | Bayer Aktiengesellschaft | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
| US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| ATE526020T1 (de) | 2000-08-10 | 2011-10-15 | Cold Spring Harbor Lab | Gesteigertes kognitives training |
| US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| AU2002333524A1 (en) | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| DE60222931T2 (de) | 2001-12-13 | 2008-07-10 | Asubio Pharma Co., Ltd. | Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung |
| WO2004024082A2 (en) | 2002-09-13 | 2004-03-25 | Irm, Llc | Highly specific modulators of gtpases for target validation |
| CN100387598C (zh) | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ATE368666T1 (de) | 2003-03-18 | 2007-08-15 | Jordanian Pharmaceutical Mfg | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US8273750B2 (en) | 2005-06-06 | 2012-09-25 | Takeda Pharmaceutical Company Limited | Organic compounds |
| DE102005061170A1 (de) | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
| JP5453086B2 (ja) | 2006-06-06 | 2014-03-26 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| JP2010527243A (ja) | 2007-05-15 | 2010-08-12 | ヘリコン セラピューティクス，インコーポレイテッド | 低分子干渉ＲＮＡ（ｓｉＲＮＡ）を用いた記憶形成に関わる遺伝子の同定方法 |
| CN101952274A (zh) | 2007-11-20 | 2011-01-19 | 默沙东公司 | 非核苷逆转录酶抑制剂 |
| AU2008335811B2 (en) | 2007-12-06 | 2012-05-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2588238T3 (es) | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| AU2009291783A1 (en) | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| KR20110098732A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| AU2009322904A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010065147A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| TW201219401A (en) | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| EP2644590A1 (en) | 2012-03-30 | 2013-10-02 | LEK Pharmaceuticals d.d. | Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts |
| MX357320B (es) | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida. |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA3128846C (en) | 2012-07-27 | 2025-05-06 | Sato Pharmaceutical Co. Ltd. | COMPOSITE OF DIFLUOROMETHYLENE |
| WO2014026328A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| JP6338601B2 (ja) | 2013-03-01 | 2018-06-06 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物 |
| TW201609713A (zh) | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| TW201611834A (en) | 2014-02-07 | 2016-04-01 | Lundbeck & Co As H | Hexahydrofuropyrroles as PDE1 inhibitors |
| RS60017B1 (sr) * | 2014-04-04 | 2020-04-30 | H Lundbeck As | Halogenovani kvinazolin-thf-amini kao pde1 inhibitori |
| US9969744B2 (en) | 2014-08-04 | 2018-05-15 | Fundación La Investigación Médica Aplicada | Compounds for use in cognition improvement |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JP2018508555A (ja) | 2015-03-16 | 2018-03-29 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体 |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| TWI609870B (zh) * | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| ES2775751T3 (es) | 2016-02-23 | 2020-07-28 | Taiho Pharmaceutical Co Ltd | Nuevo compuesto de pirimidina condensada o sal del mismo |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| US20190177327A1 (en) | 2017-10-13 | 2019-06-13 | Dart Neuroscience, Llc | Substituted methyl pyrazolopyrimidinone and methyl imidazopyrazinone compounds as pde1 inhibitors |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
-
2018
- 2018-11-26 CA CA3120971A patent/CA3120971A1/en active Pending
- 2018-11-26 MX MX2020005447A patent/MX2020005447A/es unknown
- 2018-11-26 WO PCT/US2018/062493 patent/WO2019104285A1/en not_active Ceased
- 2018-11-26 CN CN201880087700.5A patent/CN111655695B/zh active Active
- 2018-11-26 EP EP18819287.6A patent/EP3717488B1/en active Active
- 2018-11-26 ES ES18819287T patent/ES2902365T3/es active Active
- 2018-11-26 KR KR1020207018585A patent/KR102794907B1/ko active Active
- 2018-11-26 JP JP2020528933A patent/JP7254078B2/ja active Active
- 2018-11-26 US US16/766,258 patent/US11434247B1/en active Active
- 2018-11-26 DK DK18819287.6T patent/DK3717488T3/da active
- 2018-11-26 AU AU2018373258A patent/AU2018373258B2/en active Active
-
2020
- 2020-07-13 MX MX2023004603A patent/MX2023004603A/es unknown
-
2022
- 2022-09-02 US US17/902,730 patent/US12006325B2/en active Active
-
2024
- 2024-06-07 US US18/737,420 patent/US20250145633A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004603A (es) | 2023-05-08 |
| WO2019104285A1 (en) | 2019-05-31 |
| JP7254078B2 (ja) | 2023-04-07 |
| EP3717488B1 (en) | 2021-09-29 |
| EP3717488A1 (en) | 2020-10-07 |
| AU2018373258B2 (en) | 2023-03-02 |
| CA3120971A1 (en) | 2019-05-31 |
| DK3717488T3 (da) | 2021-12-13 |
| US20230295178A1 (en) | 2023-09-21 |
| US11434247B1 (en) | 2022-09-06 |
| JP2021504380A (ja) | 2021-02-15 |
| KR102794907B1 (ko) | 2025-04-14 |
| CN111655695A (zh) | 2020-09-11 |
| ES2902365T3 (es) | 2022-03-28 |
| KR20200108419A (ko) | 2020-09-18 |
| US12006325B2 (en) | 2024-06-11 |
| AU2018373258A1 (en) | 2020-07-16 |
| CN111655695B (zh) | 2025-05-27 |
| US20250145633A1 (en) | 2025-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004603A (es) | Compuestos de furanopirimidina sustituida como inhibidores de pde1. | |
| NZ725161A (en) | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors | |
| MX370188B (es) | Compuestos de piridina y pirazina sustituidos como inhibidores de pde4. | |
| NZ711598A (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| PH12020551352A1 (en) | Arginase inhibitors | |
| MX2024001394A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
| MX2024014319A (es) | Anticuerpos anti-bcma unicamente de cadena pesada | |
| WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| PH12021552147A1 (en) | Rad51 inhibitors | |
| AU2016335612B2 (en) | Dental composition | |
| MX2021004732A (es) | Anticuerpos de cadena pesada que se unen a cd38. | |
| WO2018136437A3 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| MX2020006185A (es) | Proceso para la preparacion de derivados de quinolina. | |
| MX2016001134A (es) | Derivados 1,3-disustituidos de ciclopentano. | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| MX2018001397A (es) | Polimeros de poli acido carboxilico parcialmente descarboxilados. | |
| WO2016051423A3 (en) | An improved process for the preparation of enzalutamide | |
| WO2011095812A3 (en) | Composition comprising mixed metal compounds and xanthan | |
| PE20180641A1 (es) | Uso de copolimeros de asociacion hidrofoba como aglutinantes para granular minerales que contienen metales | |
| NZ710668A (en) | Oxidatively curable coating composition | |
| MX390582B (es) | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2) | |
| MX2020008984A (es) | Compuestos de ciclohexilo sustituido como inhibidores de nop. | |
| TN2018000055A1 (en) | COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE LA HMG-CoA REDUCTASE ET UN INHIBITEUR ECA. | |
| PH12021553209A1 (en) | Agents for use in hydrometallurgical process streams | |
| CN108728721A (zh) | 新型模具钢 |